Beam Therapeutics Inc. (BEAM.MX)

390.00

+15.65

+(4.18%)

At close: April 10 at 12:01:09 PM CST

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investor's Business Daily 3 days ago

DYN

RNA

SRPT
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Key Insights Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable to...

Simply Wall St. 13 days ago

BEAM
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 14 days ago

BEAM

MGTX
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress. AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease. Also Read: Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Mi

Benzinga 17 days ago

BEAM
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3) Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025 CAMBRIDGE, Mass., April 05, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasd

GlobeNewswire 19 days ago

BEAM
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]

Insider Monkey 23 days ago

BEAM
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 23 days ago

GLPG

GLPGF

PTCT
Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and championed accelerated drug approvals, announced he was stepping down, citing irreconcilable differences with Health and Human Services Secretary Robert F. Kennedy Jr.

The Wall Street Journal 24 days ago

XBI

SRPT

BEAM
Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.

Investing.com 25 days ago

SMCI

CVNA

AMD
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

Zacks 27 days ago

BEAM
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of

GlobeNewswire 28 days ago

BEAM
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

BEAM

ITCI
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera

TipRanks last month

CHRS

PFE

ARVN
Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant, before deduct

GlobeNewswire last month

BEAM
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse E

GlobeNewswire last month

BEAM
Beam Therapeutics Full Year 2024 Earnings: Beats Expectations

Beam Therapeutics ( NASDAQ:BEAM ) Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from FY...

Simply Wall St. last month

BEAM
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected

GlobeNewswire last month

BEAM
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ETLeerink Partners Global Biopharma Conference on Monday, March 10, 2025, at 1:40 p.m. ETBarclays Global Healthcare Conference

GlobeNewswire last month

BEAM
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

While it may not be enough for some shareholders, we think it is good to see the Beam Therapeutics Inc. ( NASDAQ:BEAM...

Simply Wall St. 2 months ago

BEAM
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will

GlobeNewswire 2 months ago

BEAM

Performance Overview

Return	BEAM.MX	S&P 500 (^GSPC)
YTD	-26.55%	-6.75%
1-Year	-13.33%	+8.15%
3-Year	-51.61%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Survey

Beam Therapeutics Inc. (BEAM.MX)

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Street Calls of the Week

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

Biotech Alert: Searches spiking for these stocks today

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Beam Therapeutics Full Year 2024 Earnings: Beats Expectations

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Performance Overview